# Iovance Biotherapeutics to build $75M facility in Philadelphia

Iovance Biotherapeutics has entered into a lease agreement to build a 136,000 square foot commercial-scale production facility at the Philadelphia Navy Yard for TIL cancer therapies. The company expects to invest approximately $75 million over three years and create several hundred jobs.

- Type: New facility
- Announced: 2019-05-29
- Where: Philadelphia, Pennsylvania, United States
- Value: $75.0M
- Jobs: 200
- Starts operating: 2021
- Status: announced
- Capacity: several thousand patients annually
- Products: tumor-infiltrating lymphocyte (TIL) therapies
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Iovance Biotherapeutics](https://endata.com/companies/39660.md)

## Sources

- [globenewswire.com](https://www.globenewswire.com/de/news-release/2019/05/29/1856278/0/en/iovance-biotherapeutics-announces-new-facility-to-support-u-s-production-of-tumor-infiltrating-lymphocyte-cell-therapy-products.html), 2019-05-29: "Building our own internal production capabilities will help us reduce the cost of operations which is necessary for offering broad access to TIL therapy."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.